These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Ligand-independent activation of the androgen receptor by the differentiation agent butyrate in human prostate cancer cells. Sadar MD; Gleave ME Cancer Res; 2000 Oct; 60(20):5825-31. PubMed ID: 11059779 [TBL] [Abstract][Full Text] [Related]
3. Chronic azacitidine treatment results in differentiating effects, sensitizes against bicalutamide in androgen-independent prostate cancer cells. Gravina GL; Festuccia C; Millimaggi D; Dolo V; Tombolini V; de Vito M; Vicentini C; Bologna M Prostate; 2008 May; 68(7):793-801. PubMed ID: 18324645 [TBL] [Abstract][Full Text] [Related]
4. Reactive oxygen species mediate androgen receptor- and serum starvation-elicited downstream signaling of ADAM9 expression in human prostate cancer cells. Shigemura K; Sung SY; Kubo H; Arnold RS; Fujisawa M; Gotoh A; Zhau HE; Chung LW Prostate; 2007 May; 67(7):722-31. PubMed ID: 17342749 [TBL] [Abstract][Full Text] [Related]
5. Prosaposin upregulates AR and PSA expression and activity in prostate cancer cells (LNCaP). Koochekpour S; Lee TJ; Wang R; Culig Z; Delorme N; Caffey S; Marrero L; Aguirre J Prostate; 2007 Feb; 67(2):178-89. PubMed ID: 17044040 [TBL] [Abstract][Full Text] [Related]
6. Interleukin-8 signaling promotes androgen-independent proliferation of prostate cancer cells via induction of androgen receptor expression and activation. Seaton A; Scullin P; Maxwell PJ; Wilson C; Pettigrew J; Gallagher R; O'Sullivan JM; Johnston PG; Waugh DJ Carcinogenesis; 2008 Jun; 29(6):1148-56. PubMed ID: 18487223 [TBL] [Abstract][Full Text] [Related]
7. Androgen receptor-dependent PSA expression in androgen-independent prostate cancer cells does not involve androgen receptor occupancy of the PSA locus. Jia L; Coetzee GA Cancer Res; 2005 Sep; 65(17):8003-8. PubMed ID: 16140973 [TBL] [Abstract][Full Text] [Related]
8. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Culig Z; Hobisch A; Cronauer MV; Radmayr C; Trapman J; Hittmair A; Bartsch G; Klocker H Cancer Res; 1994 Oct; 54(20):5474-8. PubMed ID: 7522959 [TBL] [Abstract][Full Text] [Related]
9. Androgen receptor controls EGFR and ERBB2 gene expression at different levels in prostate cancer cell lines. Pignon JC; Koopmansch B; Nolens G; Delacroix L; Waltregny D; Winkler R Cancer Res; 2009 Apr; 69(7):2941-9. PubMed ID: 19318561 [TBL] [Abstract][Full Text] [Related]
10. Functional localization and competition between the androgen receptor and T-cell factor for nuclear beta-catenin: a means for inhibition of the Tcf signaling axis. Mulholland DJ; Read JT; Rennie PS; Cox ME; Nelson CC Oncogene; 2003 Aug; 22(36):5602-13. PubMed ID: 12944908 [TBL] [Abstract][Full Text] [Related]
11. Induction of bicalutamide sensitivity in prostate cancer cells by an epigenetic Puralpha-mediated decrease in androgen receptor levels. Liu X; Gomez-Pinillos A; Liu X; Johnson EM; Ferrari AC Prostate; 2010 Feb; 70(2):179-89. PubMed ID: 19790234 [TBL] [Abstract][Full Text] [Related]
12. Hormonal regulation of beta2-adrenergic receptor level in prostate cancer. Ramberg H; Eide T; Krobert KA; Levy FO; Dizeyi N; Bjartell AS; Abrahamsson PA; Taskén KA Prostate; 2008 Jul; 68(10):1133-42. PubMed ID: 18454446 [TBL] [Abstract][Full Text] [Related]
13. Gene expression changes following androgen receptor elimination in LNCaP prostate cancer cells. Eder IE; Haag P; Basik M; Mousses S; Bektic J; Bartsch G; Klocker H Mol Carcinog; 2003 Aug; 37(4):181-91. PubMed ID: 12891627 [TBL] [Abstract][Full Text] [Related]
14. Regulation of FGF8 expression by the androgen receptor in human prostate cancer. Gnanapragasam VJ; Robson CN; Neal DE; Leung HY Oncogene; 2002 Aug; 21(33):5069-80. PubMed ID: 12140757 [TBL] [Abstract][Full Text] [Related]
15. Establishment and characterization of an androgen receptor-dependent, androgen-independent human prostate cancer cell line, LNCaP-CS10. Ishikura N; Kawata H; Nishimoto A; Nakamura R; Ishii N; Aoki Y Prostate; 2010 Apr; 70(5):457-66. PubMed ID: 19902465 [TBL] [Abstract][Full Text] [Related]
16. Phosphorylation/dephosphorylation of androgen receptor as a determinant of androgen agonistic or antagonistic activity. Wang LG; Liu XM; Kreis W; Budman DR Biochem Biophys Res Commun; 1999 May; 259(1):21-8. PubMed ID: 10334909 [TBL] [Abstract][Full Text] [Related]
18. Inhibition of MAPK-signaling pathway promotes the interaction of the corepressor SMRT with the human androgen receptor and mediates repression of prostate cancer cell growth in the presence of antiandrogens. Eisold M; Asim M; Eskelinen H; Linke T; Baniahmad A J Mol Endocrinol; 2009 May; 42(5):429-35. PubMed ID: 19223455 [TBL] [Abstract][Full Text] [Related]
19. Androgen receptor activity at the prostate specific antigen locus: steroidal and non-steroidal mechanisms. Jia L; Kim J; Shen H; Clark PE; Tilley WD; Coetzee GA Mol Cancer Res; 2003 Mar; 1(5):385-92. PubMed ID: 12651911 [TBL] [Abstract][Full Text] [Related]
20. Antagonistic interaction between bicalutamide (Casodex) and radiation in androgen-positive prostate cancer LNCaP cells. Quéro L; Giocanti N; Hennequin C; Favaudon V Prostate; 2010 Mar; 70(4):401-11. PubMed ID: 19902473 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]